The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Van Den Broeck, Thomas ^a,b   Joniau, Steven ^a   Clinckemalie, Liesbeth ^b   Helsen, Christine ^b   Prekovic, Stefan ^b   Spans, Lien ^b   Tosco, Lorenzo ^a   Van Poppel, Hendrik ^a   Claessens, Frank ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYESTRADIOL; ALDOSTERONE SYNTHASE; APC; AROMATASE; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 5; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DOCETAXEL; MATRILYSIN; POLYCYCLIC AROMATIC HYDROCARBON; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; RAD51 PROTEIN; SOMATOMEDIN C; SULFOTRANSFERASE 1A1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC3 PROTEIN;

BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; INTRACELLULAR SIGNALING; MALE; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DECISION MAKING; GENETICS; PROSTATIC NEOPLASMS; RISK FACTOR;

DECISION MAKING; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84896295485     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/627510     Document Type: Review

References (114)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics 2013. CA: A Cancer Journal for Clinicians 2013 63 1 11 30
2. Schaid D. J., The complex genetic epidemiology of prostate cancer. Human Molecular Genetics 2004 13 1 R103 R121 2-s2.0-1842612064 (Pubitemid 38443804)
3. Lichtenstein P., Holm N. V., Verkasalo P. K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K., Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine 2000 343 2 78 85 2-s2.0-0034644185 10.1056/NEJM200007133430201 (Pubitemid 30451850)
4. Takata R., Akamatsu S., Kubo M., Takahashi A., Hosono N., Kawaguchi T., Tsunoda T., Inazawa J., Kamatani N., Ogawa O., Fujioka T., Nakamura Y., Nakagawa H., Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nature Genetics 2010 42 9 751 754 2-s2.0-77956637724 10.1038/ng.635
5. Xu J., Mo Z., Ye D., Wang M., Liu F., Jin G., Xu C., Wang X., Shao Q., Chen Z., Tao Z., Qi J., Zhou F., Wang Z., Fu Y., He D., Wei Q., Guo J., Wu D., Gao X., Yuan J., Wang G., Xu Y., Wang G., Yao H., Dong P., Jiao Y., Shen M., Yang J., Ou-Yang J., Jiang H., Zhu Y., Ren S., Zhang Z., Yin C., Gao X., Dai B., Hu Z., Yang Y., Wu Q., Chen H., Peng P., Zheng Y., Zheng X., Xiang Y., Long J., Gong J., Na R., Lin X., Yu H., Tao S., Feng J., Sun J., Liu W., Hsing A., Rao J., Ding Q., Wiklund F., Gronberg H., Shu X. O., Zheng W., Shen H., Jin L., Shi R., Lu D., Zhang X., Sun J., Zheng S. L., Sun Y., Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31. 2 and 19q13. 4. Nature Genetics 2012 44 11 1231 1235
6. Eeles R. A., Al Olama A. A., Benlloch S., Saunders E. J., Leongamornlert D., Tymrakiewicz M., Ghoussaini M., Luccarini C., Dennis J., Jugurnauth-Little S., Dadaev T., Neal D. E., Hamdy F. C., Donovan J. L., Muir K., Giles G. G., Severi G., Wiklund F., Gronberg H., Haiman C., Schumacher F., Henderson B. E., Le Marchand L., Lindstrom S., Kraft P., Hunter D. J., Gapstur S., Chanock S. J., Berndt S. I., Albanes D., Andriole G., Schleutker J., Weischer M., Canzian F., Riboli E., Key T. J., Travis R. C., Campa D., Ingles S., John E. M., Hayes R. B., Pharoah P. D. P., Pashayan N., Khaw K. T., Stanford J. L., Ostrander E., Signorello L. B., Thibodeau S. N., Schaid D., Maier C., Vogel W., Kibel A. S., Cybulski C., Lubinski J., Cannon-Albright L., Brenner H., Park J. Y., Kaneva R., Batra J., Spurdle A. B., Clements J., Teixeira M. R., Dicks E., Lee A., Dunning A. M., Baynes C., Conroy D., Maranian M. J., Ahmed S., Govindasami K., Guy M., Wilkinson R., Sawyer E. J., Morgan A., Dearnaley D. P., Horwich A., Huddart R., Khoo V. S., Parker C. C., Van As N. J., Woodhouse C. J., Thompson A., Dudderidge T., Ogden C., Cooper C. S., Lophatananon A., Cox A., Southey M. C., Hopper J. L., English D. R., Aly M., Adolfsson J., Xu J., Zheng S. L., Yeager M., Kaaks R., Diver W. R., Gaudet M. M., Stern M. C., Corral R., Joshi A. D., Shahabi A., Wahlfors T., Tammela T. L. J., Auvinen A., Virtamo J., Klarskov P., Nordestgaard B. G., Røder M. A., Nielsen S. F., Bojesen S. E., Siddiq A., Fitzgerald L. M., Kolb S., Kwon E. M., Karyadi D. M., Blot W. J., Zheng W., Cai Q., McDonnell S. K., Rinckleb A. E., Drake B., Colditz G., Wokolorczyk D., Stephenson R., Teerlink C., Muller H., Rothenbacher D., Sellers T., Lin H. Y., Slavov C., Mitev V., Lose F., Srinivasan S., Maia S., Paulo P., Lange E., Cooney K., Antoniou A. C., Vincent D., Bacot F., Tessier D. C., Kote-Jarai Z., Easton D. F., Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 2013 45 4 385 391
7. Gudmundsson J., Sulem P., Manolescu A., Amundadottir L. T., Gudbjartsson D., Helgason A., Rafnar T., Bergthorsson J. T., Agnarsson B. A., Baker A., Sigurdsson A., Benediktsdottir K. R., Jakobsdottir M., Xu J., Blondal T., Kostic J., Sun J., Ghosh S., Stacey S. N., Mouy M., Saemundsdottir J., Backman V. M., Kristjansson K., Tres A., Partin A. W., Albers-Akkers M. T., Godino-Ivan Marcos J., Walsh P. C., Swinkels D. W., Navarrete S., Isaacs S. D., Aben K. K., Graif T., Cashy J., Ruiz-Echarri M., Wiley K. E., Suarez B. K., Witjes J. A., Frigge M., Ober C., Jonsson E., Einarsson G. V., Mayordomo J. I., Kiemeney L. A., Isaacs W. B., Catalona W. J., Barkardottir R. B., Gulcher J. R., Thorsteinsdottir U., Kong A., Stefansson K., Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics 2007 39 5 631 637 2-s2.0-34247563453 10.1038/ng1999 (Pubitemid 46676102)
8. Gudmundsson J., Sulem P., Steinthorsdottir V., Bergthorsson J. T., Thorleifsson G., Manolescu A., Rafnar T., Gudbjartsson D., Agnarsson B. A., Baker A., Sigurdsson A., Benediktsdottir K. R., Jakobsdottir M., Blondal T., Stacey S. N., Helgason A., Gunnarsdottir S., Olafsdottir A., Kristinsson K. T., Birgisdottir B., Ghosh S., Thorlacius S., Magnusdottir D., Stefansdottir G., Kristjansson K., Bagger Y., Wilensky R. L., Reilly M. P., Morris A. D., Kimber C. H., Adeyemo A., Chen Y., Zhou J., So W.-Y., Tong P. C. Y., Ng M. C. Y., Hansen T., Andersen G., Borch-Johnsen K., Jorgensen T., Tres A., Fuertes F., Ruiz-Echarri M., Asin L., Saez B., Van Boven E., Klaver S., Swinkels D. W., Aben K. K., Graif T., Cashy J., Suarez B. K., Van Vierssen Trip O., Frigge M. L., Ober C., Hofker M. H., Wijmenga C., Christiansen C., Rader D. J., Palmer C. N. A., Rotimi C., Chan J. C. N., Pedersen O., Sigurdsson G., Benediktsson R., Jonsson E., Einarsson G. V., Mayordomo J. I., Catalona W. J., Kiemeney L. A., Barkardottir R. B., Gulcher J. R., Thorsteinsdottir U., Kong A., Stefansson K., Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics 2007 39 8 977 983 2-s2.0-34547510624 10.1038/ng2062 (Pubitemid 47185170)
9. Yeager M., Orr N., Hayes R. B., Jacobs K. B., Kraft P., Wacholder S., Minichiello M. J., Fearnhead P., Yu K., Chatterjee N., Wang Z., Welch R., Staats B. J., Calle E. E., Feigelson H. S., Thun M. J., Rodriguez C., Albanes D., Virtamo J., Weinstein S., Schumacher F. R., Giovannucci E., Willett W. C., Cancel-Tassin G., Cussenot O., Valeri A., Andriole G. L., Gelmann E. P., Tucker M., Gerhard D. S., Fraumeni J. F. Jr., Hoover R., Hunter D. J., Chanock S. J., Thomas G., Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genetics 2007 39 5 645 649 2-s2.0-34247548755 10.1038/ng2022 (Pubitemid 46676108)
10. Sun J., Zheng S. L., Wiklund F., Isaacs S. D., Li G., Wiley K. E., Kim S.-T., Zhu Y., Zhang Z., Hsu F.-C., Turner A. R., Stattin P., Liu W., Jin W. K., Duggan D., Carpten J., Isaacs W., Grönberg H., Xu J., Chang B.-L., Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Research 2009 69 1 10 15 2-s2.0-58249121582 10.1158/0008-5472.CAN-08-3464
11. Eeles R., Kote-Jarai Z., Al Olama A., Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics 2009 41 10 1116 1121
12. Haiman C. A., Chen G. K., Blot W. J., Strom S. S., Berndt S. I., Kittles R. A., Rybicki B. A., Isaacs W. B., Ingles S. A., Stanford J. L., Diver W. R., Witte J. S., Hsing A. W., Nemesure B., Rebbeck T. R., Cooney K. A., Xu J., Kibel A. S., Hu J. J., John E. M., Gueye S. M., Watya S., Signorello L. B., Hayes R. B., Wang Z., Yeboah E., Tettey Y., Cai Q., Kolb S., Ostrander E. A., Zeigler-Johnson C., Yamamura Y., Neslund-Dudas C., Haslag-Minoff J., Wu W., Thomas V., Allen G. O., Murphy A., Chang B.-L., Zheng S. L., Leske M. C., Wu S.-Y., Ray A. M., Hennis A. J. M., Thun M. J., Carpten J., Casey G., Carter E. N., Duarte E. R., Xia L. Y., Sheng X., Wan P., Pooler L. C., Cheng I., Monroe K. R., Schumacher F., Le Marchand L., Kolonel L. N., Chanock S. J., Berg D. V. D., Stram D. O., Henderson B. E., Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics 2011 43 6 570 573 2-s2.0-79957581659 10.1038/ng.839
13. Gudmundsson J., Sulem P., Rafnar T., Common sequence variants on 2p15 and Xp11. 22 confer susceptibility to prostate cancer. Nature Genetics 2008 40 3 281 283 (Pubitemid 351311771)
14. Gudmundsson J., Sulem P., Gudbjartsson D. F., Blondal T., Gylfason A., Agnarsson B. A., Benediktsdottir K. R., Magnusdottir D. N., Orlygsdottir G., Jakobsdottir M., Stacey S. N., Sigurdsson A., Wahlfors T., Tammela T., Breyer J. P., McReynolds K. M., Bradley K. M., Saez B., Godino J., Navarrete S., Fuertes F., Murillo L., Polo E., Aben K. K., Van Oort I. M., Suarez B. K., Helfand B. T., Kan D., Zanon C., Frigge M. L., Kristjansson K., Gulcher J. R., Einarsson G. V., Jonsson E., Catalona W. J., Mayordomo J. I., Kiemeney L. A., Smith J. R., Schleutker J., Barkardottir R. B., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K., Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nature Genetics 2009 41 10 1122 1126 2-s2.0-70349547128 10.1038/ng.448
15. Kote-Jarai Z., Al Olama A., Giles G., Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics 2011 43 8 785 791
16. Murabito J. M., Rosenberg C. L., Finger D., Kreger B. E., Levy D., Splansky G. L., Antman K., Hwang S.-J., A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Medical Genetics 2007 8 supplement 1, article S6 2-s2.0-35748974205 10.1186/1471-2350-8- S1-S6 (Pubitemid 351958754)
17. Cheng I., Chen G. K., Nakagawa H., He J., Wan P., Laurie C. C., Shen J., Sheng X., Pooler L. C., Crenshaw A. T., Mirel D. B., Takahashi A., Kubo M., Nakamura Y., Al Olama A. A., Benlloch S., Donovan J. L., Guy M., Hamdy F. C., Kote-Jarai Z., Neal D. E., Wilkens L. R., Monroe K. R., Stram D. O., Muir K., Eeles R. A., Easton D. F., Kolonel L. N., Henderson B. E., Le Marchand L., Haiman C. A., Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiology, Biomarkers & Prevention 2012 21 11 2048 2058
18. FitzGerald L. M., Kwon E. M., Conomos M. P., Kolb S., Holt S. K., Levine D., Feng Z., Ostrander E. A., Stanford J. L., Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiology Biomarkers and Prevention 2011 20 6 1196 1203 2-s2.0-79958029769 10.1158/1055-9965.EPI-10-1299
19. Nam R. K., Zhang W., Siminovitch K., Shlien A., Kattan M. W., Klotz L. H., Trachtenberg J., Lu Y., Zhang J., Yu C., Toi A., Loblaw D. A., Venkateswaran V., Stanimirovic A., Sugar L., Malkin D., Seth A., Narod S. A., New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biology and Therapy 2011 12 11 997 1004 2-s2.0-82755195732 10.4161/cbt.12.11.18366
20. Schumacher F. R., Berndt S. I., Siddiq A., Jacobs K. B., Wang Z., Lindstrom S., Stevens V. L., Chen C., Mondul A. M., Travis R. C., Stram D. O., Eeles R. A., Easton D. F., Giles G., Hopper J. L., Neal D. E., Hamdy F. C., Donovan J. L., Muir K., Al Olama A. A., Kote-Jarai Z., Guy M., Severi G., Grönberg H., Isaacs W. B., Karlsson R., Wiklund F., Xu J., Allen N. E., Andriole G. L., Barricarte A., Boeing H., Bueno-de-Mesquita H. B., Crawford E. D., Diver W. R., Gonzalez C. A., Gaziano J. M., Giovannucci E. L., Johansson M., Le Marchand L., Ma J., Sieri S., Stattin P., Stampfer M. J., Tjonneland A., Vineis P., Virtamo J., Vogel U., Weinstein S. J., Yeager M., Thun M. J., Kolonel L. N., Henderson B. E., Albanes D., Hayes R. B., Feigelson H. S., Riboli E., Hunter D. J., Chanock S. J., Haiman C. A., Kraft P., Genome-wide association study identifies new prostate cancer susceptibility loci. Human Molecular Genetics 2011 20 19 3867 3875 2-s2.0-80052716147 10.1093/hmg/ddr295
21. Shan J., Al-Rumaihi K., Rabah D., Al-Bozom I., Kizhakayil D., Farhat K., Al-Said S., Kfoury H., Dsouza S. P., Rowe J., Khalak H. G., Jafri S., Aigha I. I., Chouchane L., Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians. Journal of Translational Medicine 2013 11 article 121
22. Tao S., Feng J., Webster T., Jin G., Hsu F.-C., Chen S.-H., Kim S.-T., Wang Z., Zhang Z., Zheng S. L., Isaacs W. B., Xu J., Sun J., Genome-wide two-locus epistasis scans in prostate cancer using two European populations. Human Genetics 2012 131 7 1225 1234 2-s2.0-84857298626 10.1007/s00439-012-1148-4
23. Amin Al Olama A., Kote-Jarai Z., Schumacher F. R., Wiklund F., Berndt S. I., Benlloch S., Giles G. G., Severi G., Neal D. E., Hamdy F. C., Donovan J. L., Hunter D. J., Henderson B. E., Thun M. J., Gaziano M., Giovannucci E. L., Siddiq A., Travis R. C., Cox D. G., Canzian F., Riboli E., Key T. J., Andriole G., Albanes D., Hayes R. B., Schleutker J., Auvinen A., Tammela T. L. J., Weischer M., Stanford J. L., a Ostrander E., Cybulski C., Lubinski J., Thibodeau S. N., Schaid D. J., Sorensen K. D., Batra J., a Clements J., Chambers S., Aitken J., a Gardiner R., Maier C., Vogel W., ?rk T. D., Brenner H., Habuchi T., Ingles S., John E. M., Dickinson J. L., Cannon-Albright L., Teixeira M. R., Kaneva R., Zhang H. W., Lu Y. J., Park J. Y., a Cooney K., Muir K. R., a Leongamornlert D., Saunders E., Tymrakiewicz M., Mahmud N., Guy M., Govindasami K., Brien L. T. O., a Wilkinson R., Hall A. L., Sawyer E. J., Dadaev T., Morrison J., Dearnaley D. P., Horwich A., a Huddart R., Khoo V. S., Parker C. C., Van As N., Woodhouse C. J., Thompson A., Dudderidge T., Ogden C., Cooper C. S., Lophatonanon A., Southey M. C., Hopper J. L., English D., Virtamo J., Le Marchand L., Campa D., Kaaks R., Lindstrom S., Diver W. R., Gapstur S., Yeager M., Cox A., Stern M. C., Corral R., Aly M., Isaacs W., Adolfsson J., Xu J., Zheng S. L., Wahlfors T., Taari K., Kujala P., Klarskov P., Nordestgaard B. G., Røder M. A., Frikke-Schmidt R., Bojesen S. E., FitzGerald L. M., Kolb S., Kwon E. M., Karyadi D. M., Orntoft T. F., Borre M., Rinckleb A., Luedeke M., Herkommer K., Meyer A., Serth J., Marthick J. R., Patterson B., Wokolorczyk D., Spurdle A., Lose F., McDonnell S. K., Joshi A. D., Shahabi A., Pinto P., Santos J., Ray A., Sellers T. A., Lin H. Y., Stephenson R. A., Teerlink C., Muller H., Rothenbacher D., Tsuchiya N., Narita S., Cao G. W., Slavov C., Mitev V., Chanock S., Gronberg H., Haiman C. A., Kraft P., Easton D. F., Eeles R. A., A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics 2013 22 2 408 415
24. Duggan D., Zheng S. L., Knowlton M., Benitez D., Dimitrov L., Wiklund F., Robbins C., Isaacs S. D., Cheng Y., Li G., Sun J., Chang B.-L., Marovich L., Wiley K. E., Bälter K., Stattin P., Adami H.-O., Gielzak M., Yan G., Sauvageot J., Liu W., Kim J. W., Bleecker E. R., Meyers D. A., Trock B. J., Partin A. W., Walsh P. C., Isaacs W. B., Grönberg H., Xu J., Carpten J. D., Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Journal of the National Cancer Institute 2007 99 24 1836 1844 2-s2.0-38449103390 10.1093/jnci/djm250 (Pubitemid 351767196)
25. Eeles R. A., Kote-Jarai Z., Giles G. G., Olama A. A. A., Guy M., Jugurnauth S. K., Mulholland S., Leongamornlert D. A., Edwards S. M., Morrison J., Field H. I., Southey M. C., Severi G., Donovan J. L., Hamdy F. C., Dearnaley D. P., Muir K. R., Smith C., Bagnato M., Ardern-Jones A. T., Hall A. L., O'Brien L. T., Gehr-Swain B. N., Wilkinson R. A., Cox A., Lewis S., Brown P. M., Jhavar S. G., Tymrakiewicz M., Lophatananon A., Bryant S. L., Horwich A., Huddart R. A., Khoo V. S., Parker C. C., Woodhouse C. J., Thompson A., Christmas T., Ogden C., Fisher C., Jamieson C., Cooper C. S., English D. R., Hopper J. L., Neal D. E., Easton D. F., Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics 2008 40 3 316 321 2-s2.0-39749129053 10.1038/ng.90 (Pubitemid 351311772)
26. Thomas G., Jacobs K. B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chatterjee N., Welch R., Hutchinson A., Crenshaw A., Cancel-Tassin G., Staats B. J., Wang Z., Gonzalez-Bosquet J., Fang J., Deng X., Berndt S. I., Calle E. E., Feigelson H. S., Thun M. J., Rodriguez C., Albanes D., Virtamo J., Weinstein S., Schumacher F. R., Giovannucci E., Willett W. C., Cussenot O., Valeri A., Andriole G. L., Crawford E. D., Tucker M., Gerhard D. S., Fraumeni J. F. Jr., Hoover R., Hayes R. B., Hunter D. J., Chanock S. J., Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genetics 2008 40 3 310 315 2-s2.0-39749118602 10.1038/ng.91 (Pubitemid 351311773)
27. Ren S., Xu J., Zhou T., Jiang H., Chen H., Liu F., Na R., Zhang L., Wu Y., Sun J., Yang B., Gao X., Zheng S. L., Xu C., Ding Q., Sun Y., Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. Prostate 2013 73 16 1824 1835
28. Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Määpttänen A. B., Bangma C. H., Aus G., Villers A., Rebillard X., Van Kwast T. D., Blijenberg B. G., Moss S. M., De Koning H. J., Auvinen A., Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine 2009 360 13 1320 1328 2-s2.0-63249118690 10.1056/NEJMoa0810084
29. Moyer V. A., Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2012 157 2 120 134
30. Walsh P. C., Re: screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Journal of Urology 2012 188 4 1181
31. Heidenreich A., Aus G., Bolla M., Joniau S., EAU guidelines on prostate cancer. European Urology 2008 53 31 45
32. Zheng S. L., Sun J., Wiklund F., Gao Z., Stattin P., Purcell L. D., Adami H.-O., Hsu F.-C., Zhu Y., Adolfsson J., Johansson J.-E., Turner A. R., Adams T. S., Liu W., Duggan D., Carpten J. D., Chang B.-L., Isaacs W. B., Xu J., Grönberg H., Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clinical Cancer Research 2009 15 3 1105 1111 2-s2.0-61549109900 10.1158/1078-0432.CCR-08-1743
33. Salinas C. A., Koopmeiners J. S., Kwon E. M., FitzGerald L., Lin D. W., Ostrander E. A., Feng Z., Stanford J. L., Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009 69 4 363 372 2-s2.0-59849083008 10.1002/pros.20887
34. Pepe M. S., Janes H., Longton G., Leisenring W., Newcomb P., Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology 2004 159 9 882 890 2-s2.0-2342571696 10.1093/aje/kwh101 (Pubitemid 38657490)
35. Xu J., Sun J., Kader A. K., Lindström S., Wiklund F., Hsu F.-C., Johansson J.-E., Zheng S. L., Thomas G., Hayes R. B., Kraft P., Hunter D. J., Chanock S. J., Isaacs W. B., Grönberg H., Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009 69 14 1565 1572 2-s2.0-69449098701 10.1002/pros.21002
36. Sun J., Kader A. K., Hsu F.-C., Kim S.-T., Zhu Y., Turner A. R., Jin T., Zhang Z., Adolfsson J., Wiklund F., Zheng S. L., Isaacs W. B., Grönberg H., Xu J., Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2011 71 4 421 430 2-s2.0-79251483149 10.1002/pros.21256
37. Lindström S., Schumacher F. R., Cox D., Travis R. C., Albanes D., Allen N. E., Andriole G., Berndt S. I., Boeing H., Bueno-de-Mesquita H. B., Crawford E. D., Diver W. R., Gaziano J. M., Giles G. G., Giovannucci E., Gonzalez C. A., Henderson B., Hunter D. J., Johansson M., Kolonel L. N., Ma J., Marchand L. L., Pala V., Stampfer M., Stram D. O., Thun M. J., Tjonneland A., Trichopoulos D., Virtamo J., Weinstein S. J., Willett W. C., Yeager M., Hayes R. B., Severi G., Haiman C. A., Chanock S. J., Kraft P., Common genetic variants in prostate cancer risk prediction-results from the NCI breast and prostate cancer cohort consortium (BPC3). Cancer Epidemiology Biomarkers and Prevention 2012 21 3 437 444 2-s2.0-84859386051 10.1158/1055-9965.EPI-11-1038
38. Macinnis R. J., Antoniou A. C., Eeles R. A., Severi G., Al Olama A. A., Mcguffog L., Kote-Jarai Z., Guy M., O'Brien L. T., Hall A. L., Wilkinson R. A., Sawyer E., Ardern-Jones A. T., Dearnaley D. P., Horwich A., Khoo V. S., Parker C. C., Huddart R. A., Van As N., Mccredie M. R., English D. R., Giles G. G., Hopper J. L., Easton D. F., A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genetic Epidemiology 2011 35 6 549 556 2-s2.0-80051813565 10.1002/gepi.20605
39. Pashayan N., Duffy S. W., Chowdhury S., Dent T., Burton H., Neal D. E., Easton D. F., Eeles R., Pharoah P., Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. British Journal of Cancer 2011 104 10 1656 1663 2-s2.0-79955793051 10.1038/bjc.2011.118
40. Klein R. J., Hallden C., Gupta A., Savage C. J., Dahlin A., Bjartell A., Manjer J., Scardino P. T., Ulmert D., Wallström P., Vickers A. J., Lilja H., Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. European Urology 2012 61 3 471 477 2-s2.0-84856380174 10.1016/j.eururo.2011.10.047
41. Nam R. K., Zhang W. W., Trachtenberg J., Seth A., Klotz L. H., Stanimirovic A., Punnen S., Venkateswaran V., Toi A., Loblaw D. A., Sugar L., Siminovitch K. A., Narod S. A., Utility of incorporating genetic variants for the early detection of prostate cancer. Clinical Cancer Research 2009 15 5 1787 1793 2-s2.0-63449085837 10.1158/1078-0432.CCR-08-1593
42. Aly M., Wiklund F., Xu J., Isaacs W. B., Eklund M., D'Amato M., Adolfsson J., Grönberg H., Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. European Urology 2011 60 1 21 28 2-s2.0-79957946061 10.1016/j.eururo.2011.01.017
43. Xu X., Valtonen-André C., Sävblom C., Halldén C., Lilja H., Klein R. J., Polymorphisms at the microseminoprotein- β locus associated with physiologic variation in β -microseminoprotein and prostate-specific antigen levels. Cancer Epidemiology Biomarkers and Prevention 2010 19 8 2035 2042 2-s2.0-77955434607 10.1158/1055-9965.EPI-10-0431
44. Klein R. J., Halldén C., Cronin A. M., Ploner A., Wiklund F., Bjartell A. S., Stattin P., Xu J., Scardino P. T., Offit K., Vickers A. J., Grönberg H., Lilja H., Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer. Cancer Prevention Research 2010 3 5 611 619 2-s2.0-77952026425 10.1158/1940-6207.CAPR-09-0206
45. Clinckemalie L., Spans L., Dubois V., Laurent M., Helsen C., Joniau S., Claessens F., Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an Androgen Response Element. Molecular Endocrinology 2013 27 12 2028 2040
46. Bansal A., Murray D. K., Wu J. T., Stephenson R. A., Middleton R. G., Meikle A. W., Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. Journal of Clinical Endocrinology and Metabolism 2000 85 3 1272 1276 2-s2.0-0034454414 10.1210/jc.85.3.1272 (Pubitemid 32269385)
47. Gudmundsson J., Besenbacher S., Sulem P., Gudbjartsson D. F., Olafsson I., Arinbjarnarson S., Agnarsson B. A., Benediktsdottir K. R., Isaksson H. J., Kostic J. P., Gudjonsson S. A., Stacey S. N., Gylfason A., Sigurdsson A., Holm H., Bjornsdottir U. S., Eyjolfsson G. I., Navarrete S., Fuertes F., Garcia-Prats M. D., Polo E., Checherita I. A., Jinga M., Badea P., Aben K. K., Schalken J. A., Van Oort I. M., Sweep F. C., Helfand B. T., Davis M., Donovan J. L., Hamdy F. C., Kristjansson K., Gulcher J. R., Masson G., Kong A., Catalona W. J., Mayordomo J. I., Geirsson G., Einarsson G. V., Barkardottir R. B., Jonsson E., Jinga V., Mates D., Kiemeney L. A., Neal D. E., Thorsteinsdottir U., Rafnar T., Stefansson K., Genetic correction of PSA values using sequence variants associated with PSA levels. Science Translational Medicine 2010 2 62 2-s2.0-78650468754 10.1126/scitranslmed.3001513 62ra92
48. Loeb S., Carter H. B., Walsh P. C., Isaacs W. B., Kettermann A., Tanaka T., Ferrucci L., Metter E. J., Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. Journal of Urology 2009 182 1 101 105 2-s2.0-67349141550 10.1016/j.juro.2009.02. 126
49. Helfand B. T., Loeb S., Hu Q., Cooper P. R., Roehl K. A., McGuire B. B., Baumann N. A., Catalona W. J., Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. Journal of Urology 2013 189 5 1697 1701
50. Cooperberg M. R., Carroll P. R., Klotz L., Active surveillance for prostate cancer: progress and promise. Journal of Clinical Oncology 2011 29 27 3669 3676 2-s2.0-80053073767 10.1200/JCO.2011.34.9738
51. Rider J. R., Sandin F., Andrén O., Wiklund P., Hugosson J., Stattin P., Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European Urology 2013 63 1 88 96
52. Akre O., Garmo H., Adolfsson J., Lambe M., Bratt O., Stattin P., Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. European Urology 2011 60 3 554 563 2-s2.0-79961006244 10.1016/j.eururo.2011.05.047
53. Cooperberg M. R., Cowan J., Broering J. M., Carroll P. R., High-risk prostate cancer in the United States, 1990-2007. World Journal of Urology 2008 26 3 211 218 2-s2.0-44649089357 10.1007/s00345-008-0250-7
54. Briganti A., Joniau S., Gontero P., Abdollah F., Passoni N. M., Tombal B., Marchioro G., Kneitz B., Walz J., Frohneberg D., Bangma C. H., Graefen M., Tizzani A., Frea B., Karnes R. J., Montorsi F., Van Poppel H., Spahn M., Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. European Urology 2012 61 3 584 592 2-s2.0-84856377811 10.1016/j.eururo.2011.11.043
55. Joniau S., Hsu C.-Y., Lerut E., Van Baelen A., Haustermans K., Roskams T., Oyen R., Van Poppel H., A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. European Urology 2007 51 2 388 394 2-s2.0-33845597433 10.1016/j.eururo.2006.06.051 (Pubitemid 44937792)
56. Spahn M., Joniau S., Gontero P., Fieuws S., Marchioro G., Tombal B., Kneitz B., Hsu C.-Y., Van Der Eeckt K., Bader P., Frohneberg D., Tizzani A., Van Poppel H., Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. European Urology 2010 58 1 1 7 2-s2.0-77952875894 10.1016/j.eururo.2010.03.001
57. Svatek R. S., Jeldres C., Karakiewicz P. I., Suardi N., Walz J., Roehrborn C. G., Montorsi F., Slawin K. M., Shariat S. F., Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009 69 8 886 894 2-s2.0-65549127138 10.1002/pros.20938
58. Perez C. A., Chen H., Shyr Y., Courtney R., Zheng W., Cai Q., Hwang M., Jaboin J., Schleicher S., Moretti L., Wills M., Smith J. A., Lu B., The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. Journal of Urology 2010 183 5 2062 2069 2-s2.0-77950502168 10.1016/j.juro.2009.12.098
59. Huang S.-P., Huang L.-C., Ting W.-C., Chen L.-M., Chang T.-Y., Lu T.-L., Lan Y.-H., Liu C.-C., Yang W.-H., Lee H.-Z., Hsieh C.-J., Bao B.-Y., Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiology Biomarkers and Prevention 2009 18 11 3068 3074 2-s2.0-72749118780 10.1158/1055-9965.EPI-09- 0665
60. Audet-Walsh É., Bellemare J., Lacombe L., Fradet Y., Fradet V., Douville P., Guillemette C., Lévesque É., The impact of germline genetic variations in hydroxysteroid (17-Beta) dehydrogenases on prostate cancer outcomes after prostatectomy. European Urology 2012 62 1 88 96 2-s2.0-84455190209 10.1016/j.eururo.2011.12.021
61. Audet-Walsh E., Bellemare J., Nadeau G., Lacombe L., Fradet Y., Fradet V., Huang S.-P., Bao B.-Y., Douville P., Girard H., Guillemette C., Lévesque E., SRD5A polymorphisms and biochemical failure after radical prostatectomy. European Urology 2011 60 6 1226 1234 2-s2.0-80255138394 10.1016/j.eururo.2011.06.020
62. Cotignola J., Leonardi D. B., Shahabi A., Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer and Prostatic Diseases 2013 16 1 28 34
63. Dluzniewski P. J., Wang M.-H., Zheng S. L., De Marzo A. M., Drake C. G., Fedor H. L., Partin A. W., Han M., Fallin M. D., Xu J., Isaacs W. B., Platz E. A., Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiology, Biomarkers & Prevention 2012 21 10 1774 1782
64. Huang S.-P., Ting W.-C., Chen L.-M., Huang L.-C., Liu C.-C., Chen C.-W., Hsieh C.-J., Yang W.-H., Chang T.-Y., Lee H.-Z., Bao B.-Y., Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Annals of Surgical Oncology 2010 17 1 312 322 2-s2.0-74649083953 10.1245/s10434-009-0698-8
65. Chang C.-F., Pao J.-B., Yu C.-C., Huang C. Y., Huang S. P., Yang Y. P., Huang C. N., Chang T. Y., You B. J., Lee H. Z., Hour T. C., Bao B. Y., Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Annals of Surgical Oncology 2013 20 7 2446 2452
66. Huang S.-P., Lan Y.-H., Lu T.-L., Pao J.-B., Chang T.-Y., Lee H.-Z., Yang W.-H., Hsieh C.-J., Chen L.-M., Huang L.-C., Ting W.-C., Bao B.-Y., Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU International 2011 107 3 486 492 2-s2.0-79251565549 10.1111/j.1464-410X.2010.09512.x
67. Jaboin J. J., Hwang M., Lopater Z., Chen H., Ray G. L., Perez C., Cai Q., Wills M. L., Lu B., The matrix metalloproteinase-7 polymorphism RS10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2011 79 5 1330 1335 2-s2.0-79952706154 10.1016/j.ijrobp.2010.01.013
68. Wang W., Yuasa T., Tsuchiya N., Ma Z., Maita S., Narita S., Kumazawa T., Inoue T., Tsuruta H., Horikawa Y., Saito M., Hu W., Ogawa O., Habuchi T., The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. International Journal of Cancer 2009 125 12 2836 2843 2-s2.0-72449192414 10.1002/ijc.24721
69. Bachmann H. S., Heukamp L. C., Schmitz K. J., Hilburn C. F., Kahl P., Buettner R., Nückel H., Eisenhardt A., Rübben H., Schmid K. W., Siffert W., Eggert A., Schramm A., Schulte J. H., Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. International Journal of Cancer 2011 129 10 2390 2399 2-s2.0-80052961223 10.1002/ijc.25904
70. Hirata H., Hinoda Y., Kikuno N., Suehiro Y., Shahryari V., Ahmad A. E., Tabatabai Z. L., Igawa M., Dahiya R., Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. Journal of Urology 2009 181 4 1907 1912 2-s2.0-62049084351 10.1016/j.juro.2008.11.093
71. Morote J., Del Amo J., Borque A., Ars E., Hernndez C., Herranz F., Arruza A., Llarena R., Planas J., Viso M. J., Palou J., Ravents C. X., Tejedor D., Artieda M., Simn L., Martnez A., Rioja L. A., Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. Journal of Urology 2010 184 2 506 511 2-s2.0-77955470820 10.1016/j.juro.2010.03.144
72. Borque Á., del Amo J., Esteban L. M., Ars E., Hernández C., Planas J., Arruza A., Llarena R., Palou J., Herranz F., Raventós C. X., Tejedor D., Artieda M., Simon L., Martínez A., Carceller E., Suárez M., Allué M., Sanz G., Morote J., Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU International 2013 111 4 549 558
73. Langsenlehner T., Renner W., Gerger A., Hofmann G., Thurner E.-M., Kapp K. S., Langsenlehner U., Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiotherapy and Oncology 2011 98 3 387 393 2-s2.0-79952445357 10.1016/j.radonc.2011.01.021
74. Zschenker O., Raabe A., Boeckelmann I. K., Borstelmann S., Szymczak S., Wellek S., Rades D., Hoeller U., Ziegler A., Dikomey E., Borgmann K., Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiotherapy and Oncology 2010 97 1 26 32 2-s2.0-77957877713 10.1016/j.radonc.2010.01.016
75. Azria D., Betz M., Bourgier C., Sozzi W. J., Ozsahin M., Identifying patients at risk for late radiation-induced toxicity. Critical Reviews in Oncology/Hematology 2012 84 supplement 1 e35 e41 2-s2.0-77956853424 10.1016/j.critrevonc.2010.08.003
76. Barnett G. C., West C. M. L., Dunning A. M., Elliott R. M., Coles C. E., Pharoah P. D. P., Burnet N. G., Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nature Reviews Cancer 2009 9 2 134 142 2-s2.0-58949092475 10.1038/nrc2587
77. Damaraju S., Murray D., Dufour J., Carandang D., Myrehaug S., Fallone G., Field C., Greiner R., Hanson J., Cass C. E., Parliament M., Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clinical Cancer Research 2006 12 8 2545 2554 2-s2.0-33646411483 10.1158/1078-0432.CCR-05- 2703
78. De Langhe S., De Ruyck K., Ost P., Fonteyne V., Werbrouck J., De Meerleer G., De Neve W., Thierens H., Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGF β 1 gene. International Journal of Radiation OncologyBiologyPhysics 2013 85 2 393 399
79. Fachal L., Gómez-Caamaño A. G., Peleteiro P., Carballo A., Calvo-Crespo P., Sánchez-García M. S., Lobato-Busto R., Carracedo A., Vega A., Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiotherapy & Oncology 2012 105 3 321 328
80. Fachal L., Gómez-Caamaño A., Sánchez-García M., Carballo A., Peleteiro P., Lobato-Busto R., Carracedo Á., Vega A., TGF β 1 SNPs and radio-induced toxicity in prostate cancer patients. Radiotherapy and Oncology 2012 103 2 206 209 2-s2.0-84860470375 10.1016/j.radonc.2012.01.015
81. Popanda O., Marquardt J. U., Chang-Claude J., Schmezer P., Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutation Research 2009 667 1-2 58 69 2-s2.0-67649198795 10.1016/j.mrfmmm.2008.10.014
82. Suga T., Iwakawa M., Tsuji H., Ishikawa H., Oda E., Noda S., Otsuka Y., Ishikawa A., Ishikawa K.-I., Shimazaki J., Mizoe J.-E., Tsujii H., Imai T., Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics 2008 72 3 808 813 2-s2.0-52949096079 10.1016/j.ijrobp.2008.01.029
83. Parliament M. B., Murray D., Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Seminars in Radiation Oncology 2010 20 4 232 240 2-s2.0-77956455999 10.1016/j.semradonc.2010.05.003
84. Cesaretti J. A., Stock R. G., Atencio D. P., Peters S. A., Peters C. A., Burri R. J., Stone N. N., Rosenstein B. S., A Genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. International Journal of Radiation Oncology Biology Physics 2007 68 5 1410 1416 2-s2.0-34547421746 10.1016/j.ijrobp.2007.02.052 (Pubitemid 47176801)
85. Cesaretti J. A., Stock R. G., Lehrer S., Atencio D. A., Bernstein J. L., Stone N. N., Wallenstein S., Green S., Loeb K., Kollmeier M., Smith M., Rosenstein B. S., ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. International Journal of Radiation Oncology Biology Physics 2005 61 1 196 202 2-s2.0-19944386898 10.1016/j.ijrobp.2004.09.031 (Pubitemid 40039123)
86. Peters C. A., Stock R. G., Cesaretti J. A., Atencio D. P., Peters S., Burri R. J., Stone N. N., Ostrer H., Rosenstein B. S., TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics 2008 70 3 752 759 2-s2.0-38849201802 10.1016/j.ijrobp.2007.05. 023 (Pubitemid 351199705)
87. Pugh T., Keyes M., Barclay L., Delaney A., Krzywinski M., Thomas D., Novik K., Yang C., Agranovich A., McKenzie M., Morris W. J., Olive P. L., Marra M., Moore R. A., Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clinical Cancer Research 2009 15 15 5008 5016 2-s2.0-68049123415 10.1158/1078-0432.CCR- 08-3357
88. Burri R. J., Stock R. G., Cesaretti J. A., Atencio D. P., Peters S., Peters C. A., Fan G., Stone N. N., Ostrer H., Rosenstein B. S., Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiation Research 2008 170 1 49 59 2-s2.0-46449108180 10.1667/RR1219.1 (Pubitemid 351931187)
89. Barnett G. C., Coles C. E., Elliott R. M., Baynes C., Luccarini C., Conroy D., Wilkinson J. S., Tyrer J., Misra V., Platte R., Gulliford S. L., Sydes M. R., Hall E., Bentzen S. M., Dearnaley D. P., Burnet N. G., Pharoah P. D., Dunning A. M., West C. M., Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. The Lancet Oncology 2012 13 1 65 77 2-s2.0-84855321526 10.1016/S1470-2045(11)70302-3
90. Vogelzang N. J., Chodak G. W., Soloway M. S., Block N. L., Schellhammer P. E., Smith J. A. Jr., Caplan R. J., Kennealey G. T., Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995 46 2 220 226 2-s2.0-0028875365 10.1016/S0090-4295(99)80197-6
91. Soloway M. S., Chodak G., Vogelzang N. J., Block N. L., Schellhammer P. F., Smith J. A. Jr., Scott M., Kennealey G., Gau T. C., Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology 1991 37 1 46 51 2-s2.0-0026021197
92. Seidenfeld J., Samson D. J., Hasselblad V., Aronson N., Albertsen P. C., Bennett C. L., Wilt T. J., Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of Internal Medicine 2000 132 7 566 577 2-s2.0-0034603826 (Pubitemid 30171897)
93. Pienta K. J., Bradley D., Mechanisms underlying the development of androgen-independent prostate cancer. Clinical Cancer Research 2006 12 6 1665 1671 2-s2.0-33645690200 10.1158/1078-0432.CCR-06-0067
94. Choueiri T. K., Xie W., D'Amico A. V., Ross R. W., Hu J. C., Pomerantz M., Regan M. M., Taplin M.-E., Kantoff P. W., Sartor O., Oh W. K., Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009 115 5 981 987 2-s2.0-61449222946 10.1002/cncr.24064
95. Hussain M., Tangen C. M., Higano C., Schelhammer P. F., Faulkner J., Crawford E. D., Wilding G., Akdas A., Small E. J., Donnelly B., MacVicar G., Raghavan D., Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162). Journal of Clinical Oncology 2006 24 24 3984 3990 2-s2.0-33748465540 10.1200/JCO.2006.06. 4246 (Pubitemid 46630748)
96. Stewart A. J., Scher H. I., Chen M.-H., McLeod D. G., Carroll P. R., Moul J. W., D'Amico A. V., Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of Clinical Oncology 2005 23 27 6556 6560 2-s2.0-27244458795 10.1200/JCO.2005.20.966 (Pubitemid 46190248)
97. Ross R. W., Oh W. K., Xie W., Pomerantz M., Nakabayashi M., Sartor O., Taplin M.-E., Regan M. M., Kantoff P. W., Freedman M., Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. Journal of Clinical Oncology 2008 26 6 842 847 2-s2.0-39749137117 10.1200/JCO.2007.13.6804 (Pubitemid 351398074)
98. Chang B.-L., Zheng S. L., Hawkins G. A., Isaacs S. D., Wiley K. E., Turner A., Carpten J. D., Bleecker E. R., Walsh P. C., Trent J. M., Meyers D. A., Isaacs W. B., Xu J., Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Research 2002 62 6 1784 1789 2-s2.0-0037086270 (Pubitemid 34408503)
99. True L., Coleman I., Hawley S., Huang C.-Y., Gifford D., Coleman R., Beer T. M., Gelmann E., Datta M., Mostaghel E., Knudsen B., Lange P., Vessella R., Lin D., Hood L., Nelson P. S., A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 2006 103 29 10991 10996 2-s2.0-33746602208 10.1073/pnas.0603678103 (Pubitemid 44148406)
100. Teixeira A. L., Ribeiro R., Cardoso D., Pinto D., Lobo F., Fraga A., Pina F., Calais-da-Silva F., Medeiros R., Genetic polymorphism in EGF Is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clinical Cancer Research 2008 14 11 3367 3371 2-s2.0-50349084344 10.1158/1078-0432.CCR-07-5119
101. Yang M., Xie W., Mostaghel E., Nakabayashi M., Werner L., Sun T., Pomerantz M., Freedman M., Ross R., Regan M., Sharifi N., Figg W. D., Balk S., Brown M., Taplin M.-E., Oh W. K., Lee G.-S. M., Kantoff P. W., SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2011 29 18 2565 2573 2-s2.0-79959294088 10.1200/JCO.2010.31.2405
102. Teixeira A. L., Gomes M., Nogueira A., Azevedo A. S., Assis J., Dias F., Santos J. I., Lobo F., Morais A., Maurício J., Medeiros R., Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGF β 1 signaling pathway modulation. PLoS One 2013 8 8 e72419
103. Kohli M., Riska S. M., Mahoney D. W., Chai H. S., Hillman D. W., Rider D. N., Costello B. A., Qin R., Lamba J., Sahasrabudhe D. M., Cerhan J. R., Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clinic Proceedings 2012 87 3 240 246 2-s2.0-84857980986 10.1016/j.mayocp.2011.09.009
104. Bao B.-Y., Pao J.-B., Huang C.-N., Pu Y.-S., Chang T.-Y., Lan Y.-H., Lu T.-L., Lee H.-Z., Juang S.-H., Chen L.-M., Hsieh C.-J., Huang S.-P., Polymorphisms inside MicroRNAs and MicroRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clinical Cancer Research 2011 17 4 928 936 2-s2.0-79951848613 10.1158/1078-0432.CCR-10-2648
105. Huang C.-N., Huang S.-P., Pao J.-B., Chang T.-Y., Lan Y.-H., Lu T.-L., Lee H.-Z., Juang S.-H., Wu P.-P., Pu Y.-S., Hsieh C.-J., Bao B.-Y., Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Annals of Oncology 2012 23 3 707 713 2-s2.0-84857607620 10.1093/annonc/mdr264
106. Huang C.-N., Huang S.-P., Pao J.-B., Hour T.-C., Chang T.-Y., Lan Y.-H., Lu T.-L., Lee H.-Z., Juang S.-H., Wu P.-P., Huang C.-Y., Hsieh C.-J., Bao B.-Y., Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. Journal of Internal Medicine 2012 271 5 499 509 2-s2.0-84860227006 10.1111/j.1365-2796.2011.02449.x
107. Huang S. P., Bao B., Hour T., Huang C., Yu C., Liu C. C., Lee Y. C., Huang C. N., Pao J. B., Huang C. H., Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. PLoS One 2012 7 7 e41219
108. Tsuchiya N., Narita S., Inoue T., Saito M., Numakura K., Huang M., Hatakeyama S., Satoh S., Saito S., Ohyama C., Arai Y., Ogawa O., Habuchi T., Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. BMC Cancer 2013 13 1, article150
109. Tannock I. F., De Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine 2004 351 15 1502 1512 2-s2.0-4744366279 10.1056/NEJMoa040720 (Pubitemid 39315317)
110. Petrylak D. P., Tangen C. M., Hussain M. H. A., Lara P. N. Jr., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine 2004 351 15 1513 1520 2-s2.0-4744337716 10.1056/NEJMoa041318 (Pubitemid 39315318)
111. Bruno R., Vivier N., Veyrat-Follet C., Montay G., Rhodes G. R., Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Investigational New Drugs 2001 19 2 163 169 2-s2.0-0035004501 10.1023/A:1010687017717 (Pubitemid 32423721)
112. Pastina I., Giovannetti E., Chioni A., Sissung T. M., Crea F., Orlandini C., Price D. K., Cianci C., Figg W. D., Ricci S., Danesi R., Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010 10 article 511 2-s2.0-77957152348 10.1186/1471-2407-10-511
113. Sissung T. M., Danesi R., Price D. K., Steinberg S. M., De Wit R., Zahid M., Gaikwad N., Cavalieri E., Dahut W. L., Sackett D. L., Figg W. D., Sparreboom A., Association of the CYP1B1 3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics 2008 7 1 19 26 2-s2.0-38349148686 10.1158/1535-7163.MCT-07-0557
114. Sissung T. M., Baum C. E., Deeken J., Price D. K., Aragon-Ching J., Steinberg S. M., Dahut W., Sparreboom A., Figg W. D., ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clinical Cancer Research 2008 14 14 4543 4549 2-s2.0-51649129871 10.1158/1078-0432.CCR-07-4230